Streamlined European Pathway Needed For Biosimilars To Hit Smaller Targets

Development Costs Are Currently Too High For Smaller-Value Biologics To Be Viable

 
• By Dave Wallace
  
Medicines for Europe 18th biosimilars conference
Adrian van den Hoven, Esa Heinonen and Isabell Remus (from center to right) discussed the need for a streamlined European pathway for biosimilars • Source: Medicines for Europe

More from Biosimilars

More from Products